David König

6PUBLICATIONS
39CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Feb 09, 2026
Cell Therapies and Bispecific Engagers: Redefining Strategies against Checkpoint Resistance.

Heinz Läubli, David König, Marco Donia

|Nov 05, 2025
Place in therapy of key treatments for platinum-sensitive, relapsed, extensive-stage small cell lung cancer with a focus on lurbinectedin: a narrative review with case studies.

Leonid Shunyakov, Firas B Badin, Judith Hafer

|Oct 21, 2025
Treatment patterns and clinical outcomes in stage III non-small-cell lung cancer: a long-term institutional experience in Switzerland.

Altay Turunç, David König, Judith Hafer

|Apr 17, 2024
Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes.

David König, Michael T Sandholzer, Sarp Uzun

|Jan 20, 2024
Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors.

Markus Joerger, Emiliano Calvo, Heinz Laubli

|Jan 17, 2024
Corticosteroid-resistant immune-related adverse events: a systematic review.

Eveline Daetwyler, Till Wallrabenstein, David König

Pageof 1

Frequent Collaborators

4 joint publications

Heinz Läubli

3 joint publications

Alfred Zippelius

1 joint publications

Eveline Daetwyler

1 joint publications

Till Wallrabenstein